

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	RILIMOGENE GALVACIREPVEC
PRONUNCIATION	ri lim' oh jeen gal" vas i rep' vek
THERAPEUTIC CLAIM	Treatment of prostate cancer
CHEMICAL NAME	
Recombinant vaccinia virus expressing prostate specific antigen (PSA)	
TRADEMARK	PROSTVAC™
SPONSOR	BN ImmunoTherapeutics
CODE DESIGNATION	Prostvac-V
<u>CAS</u> REGISTRY NUMBER	1225283-43-1

Note: This statement of adoption on *rilimogene galvacirepvec* replaces the statement of adoption on *rilimogene gamvacirepvec*. The name *rilimogene gamvacirepvec* is hereby rescinded.